FDA Oncology Announcements

Glucocorticoid receptor antagonist × Gynecologic × Clear all

2 Announcements

FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Drugs: Lifyorli (relacorilant) · Glucocorticoid receptor antagonist, nab-paclitaxel
Condition: Gynecologic

FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Drugs: Lifyorli (relacorilant) · Glucocorticoid receptor antagonist, nab-paclitaxel
Condition: Gynecologic